Keros Therapeutics (NASDAQ:KROS) Releases Earnings Results, Beats Expectations By $0.22 EPS

Keros Therapeutics (NASDAQ:KROS - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($1.14) earnings per share for the quarter, beating analysts' consensus estimates of ($1.36) by $0.22, Zacks reports. The business had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%.

Keros Therapeutics Stock Performance

Shares of NASDAQ KROS traded up $0.07 during trading on Friday, hitting $11.08. 2,027,042 shares of the company traded hands, compared to its average volume of 1,624,140. The firm has a market capitalization of $448.82 million, a price-to-earnings ratio of -2.13 and a beta of 1.39. The business's fifty day moving average is $12.52 and its 200 day moving average is $39.49. Keros Therapeutics has a fifty-two week low of $9.77 and a fifty-two week high of $73.00.

Wall Street Analyst Weigh In

KROS has been the subject of several recent research reports. Guggenheim reissued a "neutral" rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Oppenheimer decreased their target price on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating for the company in a research report on Thursday, January 16th. William Blair lowered shares of Keros Therapeutics from an "outperform" rating to a "market perform" rating in a report on Thursday, December 12th. Jefferies Financial Group began coverage on shares of Keros Therapeutics in a research note on Tuesday, November 5th. They issued a "buy" rating on the stock. Finally, Wells Fargo & Company lowered their target price on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, Keros Therapeutics has an average rating of "Moderate Buy" and an average target price of $42.33.

Remove Ads

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.